102 related articles for article (PubMed ID: 6129302)
1. Transamination and other metabolic pathways of 3,4-dihydroxyphenylpyruvic acid in rats when simultaneously administered with L-dopa.
Lindén IB; Karlsson M; Niemi S; Penttilä A
J Pharm Pharmacol; 1982 Nov; 34(11):719-23. PubMed ID: 6129302
[TBL] [Abstract][Full Text] [Related]
2. Effects of 3,4-dihydroxyphenylpyruvic acid and L-glutamic acid on some pharmacokinetic parameters of L-dopa in the rat.
Lindén IB
J Pharm Pharmacol; 1980 May; 32(5):344-8. PubMed ID: 6104700
[TBL] [Abstract][Full Text] [Related]
3. The effect of simultaneous administration of 3,4-dihydroxyphenylpyruvic acid and L-dopa on the bioavailability of L-dopa in rat and mouse.
Hietala P; Lindén IB; Grönfors N
J Pharm Pharmacol; 1979 Apr; 31(4):205-8. PubMed ID: 36456
[TBL] [Abstract][Full Text] [Related]
4. Effects of 3,4-dihydroxyphenylpyruvic acid and its triacetylated derivative on DOPA decarboxylase.
Lindén IB; Neuvonen PJ; Vapaatalo H
Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):266-9. PubMed ID: 7136732
[TBL] [Abstract][Full Text] [Related]
5. Effect of 3,4-dihydroxyphenylpyruvic acid on the metabolism of L-DOPA in isolated perfused rat liver.
Lindén IB; Niemi S
Acta Pharmacol Toxicol (Copenh); 1982 Nov; 51(5):434-40. PubMed ID: 7164823
[TBL] [Abstract][Full Text] [Related]
6. Elevated striatal dopamine levels following administration of D-DOPA and its alpha-keto acid metabolite DHPPA: behavioral and physiological studies in vivo in the rat.
Brannan T; Prikhojan A; Yahr MD
Brain Res; 1996 Apr; 718(1-2):165-8. PubMed ID: 8773780
[TBL] [Abstract][Full Text] [Related]
7. Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian rat.
Moses J; Siddiqui A; Silverman PB
Neurosci Lett; 1996 Nov; 218(3):145-8. PubMed ID: 8945749
[TBL] [Abstract][Full Text] [Related]
8. D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in rats.
Karoum F; Freed WJ; Chuang LW; Cannon-Spoor E; Wyatt RJ; Costa E
Brain Res; 1988 Feb; 440(1):190-4. PubMed ID: 3129126
[TBL] [Abstract][Full Text] [Related]
9. Metabolic fate of 3,4-dihydroxyphenylpyruvic acid (DHPP) in rats. I. Specific transformation of DHPP to L-3,4-dihydroxyphenylalanine in vitro.
Maeda T; Shindo H
Chem Pharm Bull (Tokyo); 1977 Aug; 25(8):1992-2000. PubMed ID: 922982
[No Abstract] [Full Text] [Related]
10. The cerebral metabolism of L-dihydroxyphenylalanine. An autoradiographic and biochemical study.
Horne MK; Cheng CH; Wooten GF
Pharmacology; 1984; 28(1):12-26. PubMed ID: 6701184
[TBL] [Abstract][Full Text] [Related]
11. Metabolic difference between 3,4-dihydroxyphenylpyruvic acid (DHPP) and 3-methoxy-4-hydroxyphenylpyruvic acid (MHPP).
Maeda T; Shindo H
Chem Pharm Bull (Tokyo); 1978 Jul; 26(7):2054-7. PubMed ID: 28856
[No Abstract] [Full Text] [Related]
12. Release of synaptosomal dopamine formed from tyrosine and L-DOPA.
Bagchi SP; Bagchi P; Smith TM
Brain Res; 1980 Apr; 187(2):403-14. PubMed ID: 7370738
[TBL] [Abstract][Full Text] [Related]
13. Assessment of dopamine and its metabolites in the intracellular and extracellular compartments of the rat striatum after peripheral administration of L-[11C]dopa.
Miwa S; Gillberg PG; Bjurling P; Yumoto N; Odano I; Watanabe Y; Långström B
Brain Res; 1992 Apr; 578(1-2):122-8. PubMed ID: 1511268
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats.
Melega WP; Luxen A; Perlmutter MM; Nissenson CH; Phelps ME; Barrio JR
Biochem Pharmacol; 1990 Jun; 39(12):1853-60. PubMed ID: 2112915
[TBL] [Abstract][Full Text] [Related]
15. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
Brannan T; Martínez-Tica J; Yahr MD
Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
[TBL] [Abstract][Full Text] [Related]
16. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
17. Quantitative evaluation of the blood-brain barrier capacity to form dopamine from circulating L-DOPA.
Hardebo JE; Edvinsson L; Owman C; Rosengren E
Acta Physiol Scand; 1977 Mar; 99(3):377-84. PubMed ID: 848309
[TBL] [Abstract][Full Text] [Related]
18. β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.
Huang L; Deng M; He Y; Lu S; Ma R; Fang Y
Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):634-43. PubMed ID: 26991136
[TBL] [Abstract][Full Text] [Related]
19. Isoprenaline increases brain concentrations of administered L-dopa and L-tryptophan in the rat.
Eriksson T; Carlsson A
Psychopharmacology (Berl); 1982; 77(1):98-100. PubMed ID: 6812125
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of L-DOPA to dopamine in the substantia nigra of freely moving rats: effect of dopamine receptor agonists and antagonists.
Sarre S; Vandeneede D; Ebinger G; Michotte Y
J Neurochem; 1998 Apr; 70(4):1730-9. PubMed ID: 9523592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
